诺和诺德宣布全球裁员9000人

Group 1 - Novo Nordisk's new CEO has announced a global layoff plan, aiming to simplify organizational structure and refocus resources on growth opportunities in diabetes and obesity treatment [2][4] - The company plans to cut 9,000 jobs, which represents approximately 11% of its total workforce of 78,400, with over half of the layoffs occurring in Denmark [4][3] - The layoffs are expected to save 8 billion Danish kroner (approximately 1.2 billion USD) annually, which will be reinvested into growth areas, including commercial initiatives and R&D projects [2][4] Group 2 - Novo Nordisk's revenue for the first half of the year reached 154.944 billion Danish kroner (approximately 22.926 billion USD), reflecting an 18% year-on-year growth, although the growth rate has slowed compared to the previous year [6] - The company has lowered its full-year performance expectations for 2025 due to increased market competition and the impact of generic drugs [6] - The competitive landscape in the obesity treatment market is intensifying, with new entrants and alternative therapies gaining interest, particularly after the efficacy of semaglutide was questioned [6][5] Group 3 - The company has undergone significant leadership changes, including the replacement of the CEO and adjustments in other key positions, to better align with market demands [7] - Novo Nordisk's restructuring efforts are part of a broader trend in the pharmaceutical industry, where many companies are implementing layoffs and restructuring to enhance efficiency and reduce costs [9][10]